90y-Ibritumumab Tiuxetan (Zevalin®-BEAM/C with Autologous Stem Cell Support as Therapy for Advanced Mantle Cell Lymphoma. - Preliminary Results From the Third Nordic II Study (MCL3)

Autor: Kolstad, Arne, Laurell, Anna, Andersen, Niels S, Elonen, Erkki, Raty, Riikka, Pedersen, Lone Bredo, Bogsrud, Annik Trond Velde, Nordstrom, Marie, Gillström, Dorte Balle, Hansen, Per Boye, Bentzen, Hans, Fagerli, Unn-Merete, Meyer, Peter, Nilsson-Ehle, Herman, Jerkeman, Mats, Lehman, Anne Kristine, Lauritzen, Grete F, Sundstrom, Christer, Delabie, Jan, Karjaalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, Geisler, Christian H.

Publikováno v: Kolstad, A, Laurell, A, Andersen, N S, Elonen, E, Raty, R, Pedersen, L B, Bogsrud, A T V, Nordstrom, M, Gillström, D B, Hansen, P B, Bentzen, H, Fagerli, U-M, Meyer, P, Nilsson-Ehle, H, Jerkeman, M, Lehman, A K, Lauritzen, G F, Sundstrom, C, Delabie, J, Karjaalainen-Lindsberg, M-L, Ralfkiaer, E, Ehinger, M & Geisler, C H 2009, ' 90 y-Ibritumumab Tiuxetan (Zevalin®-BEAM/C with Autologous Stem Cell Support as Therapy for Advanced Mantle Cell Lymphoma.-Preliminary Results From the Third Nordic II Study (MCL3) ', 51 th Annual Meeting of the American Society of Hematology, New Orleans, United States, 05/12/2009-08/12/2009 .

The Nordic Lymphoma Group has since 1996 conducted three consecutive phase II trials for front-line treatment of MCL patients ≤ 65 years of age. The first protocol (MCL1) 1996-2000 introduced high-dose chemotherapy with autologous stem cell support

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::34c20d25fa1f1e32f798b48a7861362d
https://portal.findresearcher.sdu.dk/da/publications/a03c7830-0116-11df-aefb-000ea68e967b